NDAINTRAMUSCULAR, SUBCUTANEOUSSOLUTIONPriority Review
Approved
Oct 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
EVZIO (AUTOINJECTOR) (naloxone hydrochloride) by R-Pharm US is naloxone. First approved in 2016.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVZIO is an auto-injector formulation of naloxone hydrochloride, an opioid antagonist approved by the FDA in October 2016. It rapidly reverses opioid overdose by competitively blocking mu-opioid receptors, restoring normal respiration in patients experiencing acute opioid toxicity. The auto-injector design enables rapid, user-friendly administration in emergency settings without requiring medical training.
Peak8.7 years to LOE
Product is at peak lifecycle stage with established market presence, indicating stable team structure and ongoing optimization rather than rapid scaling.
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EVZIO careers center on defending and maximizing market penetration of an established, life-saving product in the critical public health overdose reversal space. Roles emphasize provider relationships, payer negotiations, and maintaining competitive positioning in a stable but strategically important market segment.
Brand Manager
Worked on EVZIO (AUTOINJECTOR) at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.